A high-risk group of PCa, defined by stage T2c or prostate-specific antigen (PSA) levels ≥ 20 ng/mL or Gleason score ≥ 8 [2], has the most potential to develop biochemical progression, local recurrence, or even metastatic disease. This evidence concerns the gene KLK3 and posterior cortical atrophy.